Medigene AG
General information
Medigene AG
Lochhamer Str. 11
Planegg
82152 Martinsried, Bavaria
Germany
Contact person: Pamela Keck, IR / Corporate Communications
Company main phone: +49 (89) 2000330
Company main fax: +49 (89) 2000333301
Website: https://www.medigene.com
Lochhamer Str. 11
Planegg
82152 Martinsried, Bavaria
Germany
Contact person: Pamela Keck, IR / Corporate Communications
Company main phone: +49 (89) 2000330
Company main fax: +49 (89) 2000333301
Website: https://www.medigene.com
| Year founded: | 1994 |
| Source of foundation: | Spin-off from company |
| Name of foundation source: | Munich Gene Center |
| No. of employees: |
Worldwide: 64 At this location: 64 |
Corporate description / mission:
Medigene AG is a publicly listed biotechnology company, which is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with a focus on T cell receptor-modified T cells (TCR-Ts) and associated projects currently in pre-clinical and clinical development.
Medigene AG is a publicly listed biotechnology company, which is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with a focus on T cell receptor-modified T cells (TCR-Ts) and associated projects currently in pre-clinical and clinical development.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 2000
Headquarters: Yes
IPO (year): 2000
Categorization
| Sector: |
|
| Subsector: |
|
| Primary therapeutic areas: |
|
| Business model: |
|
| Customer segments: |
|
Summary Products / Services / Technologies
Number of Biotech Products
| Phase I: | 1 | |
| Phase II: | 1 |
Description of products:
T cells are at the center of Medigene’s therapeutic approaches. With the aid of Medigene’s immunotherapies the patient’s own defense mechanisms are activated, and T cells harnessed in the battle against cancer. Medigene’s therapies arm the patient’s own T cells with tumor-specific T cell receptors (TCRs). The resulting TCR-Ts should thereby be able to detect and efficiently kill cancer cells.
This approach to immunotherapy aims to overcome the patient’s tolerance to cancer cells and tumor-induced immunosuppression by activating the patient’s T cells outside the body, genetically modifying them with tumor-specific TCRs and finally multiplying them. In this way, large numbers of specific T cells are made available to patients to fight the cancer within a short period of time.
T cells are at the center of Medigene’s therapeutic approaches. With the aid of Medigene’s immunotherapies the patient’s own defense mechanisms are activated, and T cells harnessed in the battle against cancer. Medigene’s therapies arm the patient’s own T cells with tumor-specific T cell receptors (TCRs). The resulting TCR-Ts should thereby be able to detect and efficiently kill cancer cells.
This approach to immunotherapy aims to overcome the patient’s tolerance to cancer cells and tumor-induced immunosuppression by activating the patient’s T cells outside the body, genetically modifying them with tumor-specific TCRs and finally multiplying them. In this way, large numbers of specific T cells are made available to patients to fight the cancer within a short period of time.
Special IP situation:
Research and development and the associated know-how is secured in 54 granted and 98 outstanding patents (2020: 47 granted and 58 outstanding patents) and forms the foundation of all our activities.
Research and development and the associated know-how is secured in 54 granted and 98 outstanding patents (2020: 47 granted and 58 outstanding patents) and forms the foundation of all our activities.
Technology used:
- TCR-T
- PD1-41BB switch receptor
- Dendritc cells
- TCR-T
- PD1-41BB switch receptor
- Dendritc cells
Financing details
| Market cap. / valuation: | EUR 70.50M |
| Money raised to date: | EUR 61.41M |
Financing details:
Data as of 1 August 2022.
Data as of 1 August 2022.
Collaborations & Clients
Partnering strategy / collaborations:
- 2seventy bio, Inc.
- BioNTech SE
- Cytovant
- 2seventy bio, Inc.
- BioNTech SE
- Cytovant
© 2023 Biotechgate by Venture Valuation